The Canadian COVID-19 Prospective Cohort Study

CANCOV

The Canadian COVID-19 Prospective Cohort Study (CANCOV) is the first Canadian study to provide a comprehensive evaluation of early to 1-year outcomes in patients with COVID-19 and their family caregivers.

​ We are an association involving multiple studies across Canada. Our research ranges from genomics and epigenomics to antibody testing and immune analyses.

​ We plan to recruit 2000 (1000 non-hospitalized and 1000 hospitalized) patients and 500 family caregivers from the four hardest-hit provinces in Canada: Quebec, Ontario, Alberta and British Columbia.



Our Research
ICU PATIENTS

Patients who are critically ill and require admission to an intensive care unit (ICU) or mechanical ventilation.

NON-ICU PATIENTS

Patients who are sick enough to require admission to acute care hospitals.

NON-HOSPITALIZED PATIENTS

Patients who are diagnosed at COVID-19 assessment centres, emergency rooms and clinics, and told to isolate at home.

OUR CO-LEAD INVESTIGATORS
CANCOV
Dr. Angela Cheung

Dr. Angela Cheung is the Founding Director of University Health Network Osteoporosis Program, the Founding Director of Centre of Excellence in Skeletal Health Assessment (CESHA), a Senior Scientist at Toronto General Research Institute, and Professor of Medicine at the University of Toronto. She is currently holding a Tier 1 Canada Research Chair in Musculoskeletal and Postmenopausal Health.

CANCOV
Dr. Margaret Herridge

Dr. Margaret S. Herridge is a Professor of Medicine, Critical Care and Pulmonary Medicine at the University Health Network; Senior Scientist in the Toronto General Research Institute; Director of Research for the Interdepartmental Division of Critical Care Medicine, University of Toronto. She obtained her MD from Queen’s University at Kingston, completed her clinical training in Respiratory and Critical Care Medicine at the University of Toronto and obtained her MPH at the Harvard School of Public Health.

Follow us